Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Adding Veliparib to Chemotherapy Improves PFS in BRCA-Mutated Breast Cancer

Key clinical point: Adding veliparib to chemotherapy improves PFS in patients with BRCA-mutated breast cancer.

Major finding: Investigator-assessed median PFS: 14.5 vs. 12.6 months with veliparib vs. placebo (HR, 0.71).

Study details: The randomized, placebo-controlled phase 3 BROCADE 3 study of 509 patients.

Disclosures: AbbVie funded the study. Dr. Diéras reported advisory/consultancy roles for several pharmaceutical companies including AbbVie. Dr. Loi reported relationships with numerous pharmaceutical companies.


Diéras V et al. ESMO 2019, Abstract LBA9.